NewAmsterdam Pharma secured a positive CHMP opinion backing EU approval for Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe) in primary hypercholesterolemia.
The European Commission decision is expected in the second half of 2026.
Menarini holds exclusive commercialization rights for obicetrapib in Europe under the partners’ licensing deal.
NAMS•
